With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Fintel reports that on May 6, 2025, Leerink Partners downgraded their outlook for Vertex Pharmaceuticals (BMV:VRTX) from Outperform to Market Perform. Capital World Investors holds 28,326K shares ...

Leerink Partnrs also issued estimates for AbbVie’s Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.33 EPS, FY2026 earnings at $14.01 EPS, FY2028 earnings at $17.67 EPS and FY2029 earnings ...

The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc. Analysts arrive at stock ratings after doing extensive ...

Fintel reports that on April 30, 2025, Leerink Partners downgraded their outlook for NeoGenomics (BMV:NEO) from Outperform to Market Perform. There are 666 funds or institutions reporting ...

Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings per share of $5.20 for the year, down from their previous […] Skip to main content Analyst Ratings ...